



Pharmaceuticals Limited

**Registered & Corporate Office :**

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,  
Opp. SBI Executive Enclave, Banjara Hills,  
Hyderabad - 500 034, Telangana, INDIA.

Tel : +91-40-2525 9999, Fax : +91-40-2525 9889

CIN : L24239TG1987PLC008066

Email: info@smspharma.com, www.smspharma.com

Date: 20<sup>th</sup> January, 2022

To,  
Listing / Compliance Department  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai - 400 001

Listing / Compliance Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C-1, Block G,  
Bandra-Kurla Complex, Bandra (East),  
Mumbai- 400051

BSE Code: – 532815

NSE Code: SMSPHARMA

Dear Sir/Madam

Sub: Press Release – Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We are enclosing here with press release dated 20<sup>th</sup> January, 2022 regarding the Company receives non-exclusive license to manufacture and supply of molnupiravir (an oral COVID-19 medicine) through the Medicine Patent Pool (MPP).

Kindly take the same on record.

Thanking you.

Yours Faithfully,  
For SMS Pharmaceuticals Limited

V. S. Venkatish  
Company Secretary & Compliance Officer  
ICSI M. No.: A21785

## Press Release

### **SMS Pharmaceuticals Limited receives non-exclusive license to manufacture and supply of molnupiravir (an oral COVID-19 medicine) through the Medicine Patent Pool (MPP)**

**Hyderabad, January 20, 2022:** SMS Pharmaceuticals Limited has received a non-exclusive license through the Medicines Patent Pool (MPP) to manufacture molnupiravir, an investigational oral antiviral COVID-19 medicine, to increase broad access of treatment in 105 low- and middle- income countries (LMIC).

MSD (NYSE: MRK), a trade name of Merck & Co., Inc, Kenilworth, NJ, USA., has entered into an agreement to license this pill for wider distribution with patent group. Under the terms of the agreement, MPP, through the license granted by MSD, will be permitted to further license non-exclusive sublicences to manufacturers and diversify the manufacturing base for the supply of molnupiravir to countries covered by the MPP Licence, subject to local regulatory authorization.

Molnupiravir is the first oral, direct-acting antiviral shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favourable safety and tolerability profile. Last month, the U.K. became the first country to approve molnupiravir and an advisory panel convened by the U.S. FDA that the known and potential benefits of molnupiravir outweigh its known and potential risks for the treatment of mild to moderate COVID-19 in high risk adult patients who are within five days of symptom onset. Molnupiravir is the first oral antiviral medicine available for COVID-19 therapy.

**Commenting on this Mr. P. Vamsi Krishna, Executive Director – SMS Pharmaceuticals Limited said,** *“It gives us an immense pleasure to be a part of humanitarian mission by MPP and MSD to provide affordable access of low-cost oral COVID-19 medicine for LMIC countries. We, at SMS Pharma firmly believe that the entire pharma value chain must work together to provide an access of breakthroughs, medical discoveries to LMIC countries. We are delighted to work with MPP to further strengthen this belief.*

*I am incredibly proud and also very excited to show what we’re capable of offering to our customers. This is an important milestone and an external validation to the company’s ability to provide frugal, world class products while maintaining the quality.”*

#### **About SMS Pharmaceuticals Limited**

Established in 1990, SMS Pharma is a global player in API and intermediates manufacturing having a strong research and manufacturing team supported by state-of-the-art facilities. The Company has capabilities in wide range of APIs / intermediates and has handled varied process reactions and reactor volumes up to 2,000 KL. The company undertakes contract manufacturing of API, Intermediates (advanced and basic) offering a competitive advantage to its clients especially in late stage lifecycle of products. The Company has demonstrated its manufacturing excellence over the past 2 decades in a broad portfolio of therapeutic segments by being a trusted partner to a customer base in over 70 countries (including clientele in top 20 pharma companies). With 2 manufacturing facilities (two USFDA inspected), 2 pilot plants, 1 R&D center and 1 USFDA approved Independent Testing Laboratory, SMS Pharma is an ideal partner for custom synthesis, process development and mass manufacturing of customer’s own discovery products.

For more information, please visit [smspharma.com](http://smspharma.com)

### **Safe Harbor**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

**For more information please contact:**



**SMS Pharmaceuticals Limited**  
CIN: L24239TG1987PLC008066

Mr. V.S. Venkatesh  
Email: [cs@smspharma.com](mailto:cs@smspharma.com)

Contact no.: +91 9989322673

**SGA** Strategic Growth Advisors

**Strategic Growth Advisors Pvt. Ltd.**  
CIN: U74140MH2010PTC204285

Mr. Jigar Kavaiya / Mr. Chinmay Madgulkar  
Email: [jigar.kavaiya@sgapl.net](mailto:jigar.kavaiya@sgapl.net) / [chinmay.m@sgapl.net](mailto:chinmay.m@sgapl.net)

Contact no.: +91 9920602034 / +91 9860088296